Latest News and Press Releases
Want to stay updated on the latest news?
-
伊利诺伊州维尔梅特, March 31, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。该公司今天宣布发表了一项同行评审研究，标题为“对应纤溶酶原激活剂的工程抗体片段用于通过正电子发射断层显像技术对三阴性乳腺癌的快速勾画。”...
-
WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
-
Validive® Phase 2b/3 VOICE Clinical Trial CommencedCamsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021MNPR-101-Conjugate Data Published in European Journal of Cancer WILMETTE,...
-
伊利诺伊州维尔梅特, March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，主要从事延长癌症患者寿命或改善其生活质量专有疗法研发，今日宣布与连续医疗科技创业家Andrew...
-
WILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
-
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
-
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
-
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
-
伊利诺伊州威尔梅特, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，专注于开发延长癌症患者寿命或提高其生活质量的专利疗法。该公司今天宣布，已在Validive®的2b/3期VOICE（prevention of chemoradiotherapy-induced...
-
伊利诺伊州威尔梅特, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布其一篇同行评议研究的论文在《European Journal of...